EA.PVCHealth@unisa.edu.au
Professor David Waugh is the Inaugural Pro-Vice Chancellor for Health and Medical Research and Engagement at University of South Australia, a role focused on developing inter-disciplinary and impactful research programmes that provide transformative solutions to inform improved patient outcomes and future healthcare practice. He was formerly the Head of School for Biomedical Sciences at Queensland University of Technology and prior to emigrating to Australia, he served as Director of the Patrick G Johnston Centre for Cancer Research at Queen’s University and the CRUK Belfast Cancer Centre, developing an ecosystem that integrated academic discovery science with entrepreneurial biotech research and development and finally... Read more
About me
Professor David Waugh is the Inaugural Pro-Vice Chancellor for Health and Medical Research and Engagement at University of South Australia, a role focused on developing inter-disciplinary and impactful research programmes that provide transformative solutions to inform improved patient outcomes and future healthcare practice. He was formerly the Head of School for Biomedical Sciences at Queensland University of Technology and prior to emigrating to Australia, he served as Director of the Patrick G Johnston Centre for Cancer Research at Queen’s University and the CRUK Belfast Cancer Centre, developing an ecosystem that integrated academic discovery science with entrepreneurial biotech research and development and finally implementation in innovative early-phase clinical trials.
A Professor of Molecular Oncology and Therapeutics, David is an internationally-respected prostate cancer researcher focusing on using scientific discoveries to inform the use of new therapies in treating men with prostate cancer. He was the Founding Director of the FASTMAN Movember/PCUK Centre of Excellence (2013-2018) between Queen’s University Belfast and the University of Manchester in the UK, a programme delivering biomarkers and a series of translational studies to improve the outcomes of prostate cancer patients being treated for high-risk disease using radiotherapy protocols. His own research has focused on disrupting the inflammatory storms driven by chemokine signalling that underpin the aggressive and life-threatening behaviour of specific, genetically-defined subtypes of prostate cancer.
Research
Excludes commercial-in-confidence projects.
Targeting Inhibitory kappa B kinase α (IKKα): a new treatment paradigm for inflammatory-driven cancers, Medical Research Council, 28/08/2024 - 27/08/2027
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2023 |
Open access
11
12
|
2023 |
Open access
17
|
2021 |
Open access
8
8
|
2021 |
Open access
4
3
|
2020 |
Open access
|
2019 |
Open access
141
138
|
2019 |
6
6
|
2018 |
Open access
66
65
|
2018 |
Open access
12
12
|
2018 |
Open access
18
20
|
2018 |
Open access
28
26
|
2017 |
Open access
26
23
|
2016 |
Open access
30
29
|
2016 |
17
18
|
2016 |
Open access
123
114
|
2015 |
Open access
88
81
|
2015 |
Open access
46
46
|
2015 |
Open access
18
|
External engagement & recognition
Organisation | Country |
---|---|
Almac (United Kingdom) | UNITED KINGDOM |
Astex Pharmaceuticals | UNITED STATES |
BC Cancer Agency | CANADA |
Beaumont Hospital | IRELAND |
Cantonal Hospital, St. Gallen | SWITZERLAND |
Duke University | UNITED STATES |
Erasmus MC Cancer Institute | NETHERLANDS |
Heinrich-Heine University Medical Center | GERMANY |
Hospital Universitari i Politcnic La Fe | SPAIN |
Imperial College of Science, Technology and Medicine | UNITED KINGDOM |
Institute of Cancer Research | UNITED KINGDOM |
Institute of Oncology Research | SWITZERLAND |
Istituti di Ricovero e Cura a Carattere Scientifico | ITALY |
Johns Hopkins University | UNITED STATES |
Memorial Sloan Kettering Cancer Centre | UNITED STATES |
National Cancer Centre Singapore | SINGAPORE |
National University of Singapore | SINGAPORE |
Oncoceutics (United States) | UNITED STATES |
Prostate Cancer Foundation | UNITED STATES |
Queen's University Belfast | UNITED KINGDOM |
Queensland University of Technology | AUSTRALIA |
Radboud University Nijmegen Medical Centre | NETHERLANDS |
Royal Marsden Hospital | UNITED KINGDOM |
Spanish National Cancer Research Centre | SPAIN |
University of Antwerp | BELGIUM |
University of Manchester | UNITED KINGDOM |
University of Oxford | UNITED KINGDOM |
University of Padua | ITALY |
University of Twente | NETHERLANDS |